Key takeaway: Apollo Hospitals Enterprise Limited's investor presentation for Q1 FY27 reported a consolidated revenue growth of 21% to INR 70,435 million, with EBITDA increasing by 28% to INR 10,920 million. The presentation highlighted a 34% rise in PAT to INR 5,805 million. The healthcare services segment saw a 22% revenue increase, driven by a 13% growth in inpatient volume. The company commissioned five new hospitals, contributing to an overall operational capacity of 9,857 beds. The diagnostics and retail health segments also showed significant growth, with diagnostics revenue up by 31% year-over-year. Management noted the successful implementation of AI technologies across various services and emphasized ongoing expansion plans in both existing and new markets. The presentation included a detailed overview of financial metrics and operational performance across different regions and segments.

Key takeaway: The earnings call transcript for Apollo Hospitals Enterprise Limited, dated May 25, 2026, provides information regarding the audited financial results for the three months and year ended March 31, 2026. The document states that the transcript of the presentation made on May 21, 2026, is available on the company's website. It includes contact details for investor relations and regulatory compliance information, including references to the National Stock Exchange and Bombay Stock Exchange. The communication is signed by the Senior Vice President of Finance and Company Secretary, indicating formal acknowledgment of the financial results and compliance with SEBI regulations.

Key takeaway: Apollo Hospitals Enterprise Limited's investor presentation detailed the financial results for the quarter and year ended March 31, 2026. The presentation reported a consolidated revenue growth of 18% year-over-year (YoY) to ₹66,055 million for Q4 FY26, with EBITDA increasing by 31% to ₹10,109 million. The consolidated profit after tax (PAT) rose by 36% to ₹5,292 million. For the full fiscal year, total revenues grew by 16% to ₹252,285 million, with EBITDA up 25% to ₹37,693 million and PAT increasing by 34% to ₹19,415 million. The document highlighted the commissioning of four new hospitals and emphasized growth in various segments, including healthcare services and digital health. Management noted a significant increase in patient volumes and revenue per inpatient, alongside ongoing expansion plans across multiple regions.

Key takeaway: The document is a communication from Apollo Hospitals Enterprise Limited to the Bombay Stock Exchange and the National Stock Exchange, informing them about the availability of the transcript for the earnings call held on February 11, 2026. This call discussed the unaudited financial results for the three and nine months ended December 31, 2025. The company provided a link to access the transcript on its website, complying with SEBI regulations regarding disclosure requirements. S.M. Krishnan, the Senior Vice President – Finance and Company Secretary, signed the communication.

Key takeaway: Apollo Hospitals Enterprise Limited reported its financial results for the third quarter and nine months ended December 31, 2025. The presentation highlighted a consolidated revenue growth of 17% year-over-year to ₹64,774 million, with EBITDA increasing by 27% to ₹9,653 million. The consolidated profit after tax (PAT) rose by 35% to ₹5,023 million. The healthcare services segment saw a revenue increase of 14%, driven by a 4% rise in inpatient volume and an 11% increase in average revenue per inpatient. The diagnostics and retail health segment also performed well, with a 20% revenue growth. The company emphasized its expansion plans, including new hospital acquisitions and operationalizing additional beds. Management noted the successful implementation of various clinical initiatives and the growth of its digital health platform, Apollo 24|7, which recorded significant user engagement and transaction growth.

Key takeaway: Apollo Hospitals Enterprise Limited reported its financial results for the third quarter and nine months ended December 31, 2025. The presentation highlighted a consolidated revenue growth of 17% year-over-year to ₹64,774 million, with EBITDA increasing by 27% to ₹9,653 million. The consolidated profit after tax (PAT) rose by 35% to ₹5,023 million. The healthcare services segment saw a revenue increase of 14%, driven by a 4% rise in inpatient volume and an 11% increase in average revenue per inpatient. The diagnostics and retail health segment also performed well, with a 20% revenue growth. The company emphasized its expansion plans, including the operationalization of new hospitals and the introduction of new healthcare services. Management noted the importance of digital health initiatives and the growth of its omni-channel healthcare platform, Apollo 24|7, which has seen significant user engagement.